Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8558 Monotherapy in ART-Naïve HIV-1
NCT03859739Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of islatravir in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) Concentration, Number of Participants Experiencing ≥1 Adverse Event and 1 more. Started Apr 2019; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03859739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03859739.